Black Diamond Therapeutics/$BDTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Black Diamond Therapeutics
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Ticker
$BDTX
Sector
Primary listing
Employees
21
Headquarters
BDTX Metrics
BasicAdvanced
$116M
5.21
$0.39
3.43
-
Price and volume
Market cap
$116M
Beta
3.43
52-week high
$4.94
52-week low
$1.20
Average daily volume
596K
Financial strength
Current ratio
8.419
Quick ratio
8.178
Long term debt to equity
13.428
Total debt to equity
16.737
Profitability
EBITDA (TTM)
20.195
Gross margin (TTM)
100.00%
Net profit margin (TTM)
31.95%
Operating margin (TTM)
28.39%
Revenue per employee (TTM)
$3,330,000
Management effectiveness
Return on assets (TTM)
9.35%
Return on equity (TTM)
22.88%
Valuation
Price to earnings (TTM)
5.205
Price to revenue (TTM)
1.649
Price to book
1.03
Price to tangible book (TTM)
1.03
Price to free cash flow (TTM)
3.898
Free cash flow yield (TTM)
25.65%
Free cash flow per share (TTM)
0.521
Growth
Earnings per share change (TTM)
-130.71%
3-year earnings per share growth (CAGR)
-46.24%
What the Analysts think about BDTX
Analyst ratings (Buy, Hold, Sell) for Black Diamond Therapeutics stock.
BDTX Financial Performance
Revenues and expenses
BDTX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Black Diamond Therapeutics stock?
Black Diamond Therapeutics (BDTX) has a market cap of $116M as of March 28, 2026.
What is the P/E ratio for Black Diamond Therapeutics stock?
The price to earnings (P/E) ratio for Black Diamond Therapeutics (BDTX) stock is 5.21 as of March 28, 2026.
Does Black Diamond Therapeutics stock pay dividends?
No, Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders as of March 28, 2026.
When is the next Black Diamond Therapeutics dividend payment date?
Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Black Diamond Therapeutics?
Black Diamond Therapeutics (BDTX) has a beta rating of 3.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.